ArticleCureus2025
A Case of Pediatric Renal Cell Carcinoma With TFE3 Rearrangement Treated With Robot-Assisted Partial Nephrectomy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is uncommon in the pediatric population, and the TFE3-rearranged RCC (tRCC) subtype is characterized by translocation at Xp11.2. While robot-assisted partial nephrectomy (RAPN) is established in adult RCC treatment, its use in pediatric malignancies remains limited. We report the case of an 11-year-old boy with a progressively enlarging right renal cystic mass. Contrast-enhanced computed tomography revealed an enhancing solid component. RAPN was performed using the da Vinci Xi system, with no perioperative complications. Histopathology confirmed tRCC based on morphology and immunohistochemistry despite a negative TFE3 split FISH (fluorescence in situ hybridization) result. The patient was discharged on postoperative day 6 and remained recurrence-free at 24 months. This case illustrates the feasibility and efficacy of RAPN for pediatric RCC, suggesting that with careful planning and selection, nephron-sparing surgery may be applicable in selected pediatric oncology cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.